dc.contributor.author
Miravitlles Fernández, Marc
dc.contributor.author
Sliwinski, Pawel
dc.contributor.author
Rhee, Chin Kook
dc.contributor.author
Costello, Richard W.
dc.contributor.author
Carter, Victoria
dc.contributor.author
Tan, Jessica
dc.contributor.author
Lapperre, Therese Sophie
dc.contributor.author
Alcazar, Bernardino
dc.contributor.author
Gouder, Caroline
dc.contributor.author
Esquinas López, Cristina
dc.contributor.author
García Rivero, Juan Luis
dc.contributor.author
Kemppinen, Anu
dc.contributor.author
Tee, Augustine
dc.contributor.author
Roman Rodríguez, Miguel
dc.contributor.author
Soler Cataluña, Juan José
dc.contributor.author
Price, David B.
dc.date.issued
2019-04-09T12:29:21Z
dc.date.issued
2019-04-09T12:29:21Z
dc.date.issued
2018-03-01
dc.date.issued
2019-04-09T12:29:22Z
dc.identifier
https://hdl.handle.net/2445/131924
dc.description.abstract
BACKGROUND: The concept of clinical control in COPD has been developed to help in treatment decisions, but it requires validation in prospective studies. METHOD: This international, multicenter, prospective study aimed to validate the concept of control in COPD [control = stability (no exacerbations or impairment in CAT scores) + low impact (low level of symptoms)]. Data from the screening visit was used to: investigate the level of control, compare characteristics of patients according to the control status, and perform a sensitivity analysis of the levels of control using either clinical criteria or questionnaires (COPD Assessment Test -CAT- or Clinical COPD Questionnaire -CCQ-). RESULTS: A total of 314 patients were analysed, mean age was 68.5 years and mean FEV1 was 52.6% of predicted. According to the prespecified criteria 21% of patients were classified as controlled, all of them with mild/moderate COPD (Body mass index, Obstruction, Dyspnea and Exacerbations, -BODEx-index <5). A high level of dyspnea, a high CAT score or an exacerbation in the previous 3 months were found, using univariate analysis, to be the main reasons for patients not being classified as controlled. Multivariate analysis showed that female sex, chronic bronchitis and having exacerbations in the previous year were associated with uncontrolled COPD. Changing the severity cut off of BODEx from 5 to 3 did not change significantly the percentage of patients fulfilling the criteria of control. CONCLUSIONS: The proposed criteria of control were only fulfilled by 21% of patients. The suggested cut offs and their predictive value for poor outcomes need to be refined in prospective studies.
dc.format
application/pdf
dc.publisher
Elsevier B.V.
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1016/j.rmed.2018.01.019
dc.relation
Respiratory Medicine, 2018, vol. 136, p. 8-14
dc.relation
https://doi.org/10.1016/j.rmed.2018.01.019
dc.rights
cc-by-nc-nd (c) Elsevier B.V., 2018
dc.rights
http://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil)
dc.subject
Malalties pulmonars obstructives cròniques
dc.subject
Assaigs clínics
dc.subject
Chronic obstructive pulmonary diseases
dc.subject
Clinical trials
dc.title
Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion